Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).

Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group.

Appl Health Econ Health Policy. 2019 Oct;17(5):615-627. doi: 10.1007/s40258-019-00494-3.

2.

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.

Pollock RF, Muduma G.

Adv Ther. 2019 Aug;36(8):1821-1825. doi: 10.1007/s12325-019-00993-8. Epub 2019 Jun 1. No abstract available.

3.
4.

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.

Gæde P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP.

Diabetes Ther. 2019 Aug;10(4):1297-1317. doi: 10.1007/s13300-019-0630-6. Epub 2019 May 16. Erratum in: Diabetes Ther. 2019 May 31;:.

6.

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallén N, Luckevich M, Tutkunkardas D, Zinman B; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1706-1714. doi: 10.1111/dom.13730. Epub 2019 Apr 14.

7.

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.

Johansen P, Hunt B, Iyer NN, Dang-Tan T, Pollock RF.

Adv Ther. 2019 May;36(5):1190-1199. doi: 10.1007/s12325-019-00915-8. Epub 2019 Mar 14. Erratum in: Adv Ther. 2019 Apr 12;:.

8.

A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.

Pollock RF, Muduma G.

Expert Rev Hematol. 2019 Feb;12(2):129-136. doi: 10.1080/17474086.2019.1575202. Epub 2019 Feb 19.

PMID:
30689458
9.

A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.

Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M.

J Comp Eff Res. 2019 Mar;8(4):229-240. doi: 10.2217/cer-2018-0073. Epub 2019 Jan 15.

10.

An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.

Pollock RF, Muduma G.

Adv Ther. 2018 Dec;35(12):2128-2137. doi: 10.1007/s12325-018-0827-5. Epub 2018 Nov 19.

PMID:
30456520
11.

Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O'Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM.

Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9.

12.

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.

Pollock RF, Chubb B, Valentine WJ, Heller S.

Diabetes Metab Syndr Obes. 2018 May 16;11:217-226. doi: 10.2147/DMSO.S156739. eCollection 2018.

13.

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group.

Diabetes Ther. 2018 Jun;9(3):1217-1232. doi: 10.1007/s13300-018-0430-4. Epub 2018 Apr 30.

14.

An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland.

Pollock RF, Meckley LM.

Clinicoecon Outcomes Res. 2018 Apr 10;10:223-229. doi: 10.2147/CEOR.S155641. eCollection 2018.

15.

Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.

Lane W, Weatherall J, Gundgaard J, Pollock RF.

J Med Econ. 2018 May;21(5):542. doi: 10.1080/13696998.2018.1452510. Epub 2018 Mar 21. No abstract available.

PMID:
29560778
16.

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.

Wilkinson L, Hunt B, Johansen P, Iyer NN, Dang-Tan T, Pollock RF.

Diabetes Ther. 2018 Jun;9(3):951-961. doi: 10.1007/s13300-018-0402-8. Epub 2018 Mar 19.

17.

Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation.

Valentine WJ, Van Brunt K, Boye KS, Pollock RF.

Appl Health Econ Health Policy. 2018 Jun;16(3):357-366. doi: 10.1007/s40258-018-0379-5. Review.

PMID:
29525908
18.

Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden.

Jendle J, Ericsson Å, Hunt B, Valentine WJ, Pollock RF.

Diabetes Ther. 2018 Feb;9(1):87-99. doi: 10.1007/s13300-017-0344-6. Epub 2017 Dec 4.

19.

Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.

Pollock RF, Muduma G.

Expert Opin Drug Deliv. 2017 Dec;14(12):1439-1446. doi: 10.1080/17425247.2017.1393412. Epub 2017 Oct 24.

PMID:
29032713
20.

Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.

Lane WS, Weatherall J, Gundgaard J, Pollock RF.

J Med Econ. 2018 Feb;21(2):144-151. doi: 10.1080/13696998.2017.1384383. Epub 2017 Oct 12. Erratum in: J Med Econ. 2018 May;21(5):542.

PMID:
28945173
21.

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.

Pollock RF, Muduma G.

Clinicoecon Outcomes Res. 2017 Aug 10;9:475-483. doi: 10.2147/CEOR.S139525. eCollection 2017.

22.

The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus.

Valentine WJ, Pollock RF, Saunders R, Bae J, Norrbacka K, Boye K.

Value Health. 2017 Jul - Aug;20(7):985-991. doi: 10.1016/j.jval.2016.12.001. Epub 2017 May 4.

23.

Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis.

Saunders R, Struys MMRF, Pollock RF, Mestek M, Lightdale JR.

BMJ Open. 2017 Jun 30;7(6):e013402. doi: 10.1136/bmjopen-2016-013402. Review.

24.

Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant.

Muduma G, Saunders R, Odeyemi I, Pollock RF.

PLoS One. 2016 Nov 3;11(11):e0160421. doi: 10.1371/journal.pone.0160421. eCollection 2016. Review.

26.

A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.

Pollock RF, Tikkanen CK.

J Med Econ. 2017 Mar;20(3):213-220. doi: 10.1080/13696998.2016.1245663. Epub 2016 Oct 24.

PMID:
27705031
27.

A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.

Muduma G, Odeyemi I, Pollock RF.

J Med Econ. 2016 Oct;19(10):995-1002. doi: 10.1080/13696998.2016.1189921. Epub 2016 Jun 1.

PMID:
27172118
28.

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF.

Adv Ther. 2016 Mar;33(3):345-56. doi: 10.1007/s12325-016-0292-y. Epub 2016 Feb 23. Review.

PMID:
26905265
29.

Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.

Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF.

J Med Econ. 2016 Jul;19(7):672-83. doi: 10.3111/13696998.2016.1154567. Epub 2016 Mar 2.

PMID:
26882484
30.

Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.

Muduma G, Odeyemi I, Pollock RF.

J Med Econ. 2015;18(12):1050-9. doi: 10.3111/13696998.2015.1074584. Epub 2015 Aug 26.

PMID:
26201252
31.

Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.

Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM.

Diabetes Res Clin Pract. 2015 Jul;109(1):95-103. doi: 10.1016/j.diabres.2015.04.023. Epub 2015 Apr 21.

PMID:
25989713
32.

An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices.

Pollock RF, Kappelgaard AM, Seitz L.

Expert Opin Drug Deliv. 2015 Mar;12(3):353-60. doi: 10.1517/17425247.2015.1003805. Epub 2015 Jan 22.

PMID:
25614081
33.
34.

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF.

Patient Prefer Adherence. 2014 Mar 28;8:391-9. doi: 10.2147/PPA.S60213. eCollection 2014.

35.

Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.

Ericsson Å, Pollock RF, Hunt B, Valentine WJ.

J Med Econ. 2013 Dec;16(12):1442-52. doi: 10.3111/13696998.2013.852099. Epub 2013 Oct 25.

PMID:
24147661
36.

Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.

Pollock RF, Qian Y, Wisniewski T, Seitz L, Kappelgaard AM.

Med Devices (Auckl). 2013 Aug 1;6:107-14. doi: 10.2147/MDER.S45909. eCollection 2013.

37.

A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.

Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ.

Adv Ther. 2012 Dec;29(12):1051-66. doi: 10.1007/s12325-012-0065-1. Epub 2012 Nov 22.

PMID:
23179373
38.

Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK.

Pollock RF, Chilcott J, Muduma G, Valentine WJ.

J Med Econ. 2013;16(2):249-59. doi: 10.3111/13696998.2012.751388. Epub 2012 Dec 5.

PMID:
23163313
39.

Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.

Pollock RF, Muduma G, Valentine WJ.

Diabetes Obes Metab. 2013 Feb;15(2):121-9. doi: 10.1111/j.1463-1326.2012.01692.x. Epub 2012 Sep 20.

PMID:
22882321
40.

Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ.

J Med Econ. 2012;15(5):977-86. doi: 10.3111/13696998.2012.692340. Epub 2012 May 23.

PMID:
22563742
41.

A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.

Pollock RF, Curtis BH, Valentine WJ.

J Med Econ. 2012;15(4):766-75. doi: 10.3111/13696998.2012.675890. Epub 2012 Apr 4.

PMID:
22413830
42.

Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.

Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M.

Diabet Med. 2012 Mar;29(3):303-12. doi: 10.1111/j.1464-5491.2011.03461.x.

PMID:
21951030
43.

A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.

Lippuner K, Pollock RF, Smith-Palmer J, Meury T, Valentine WJ.

Appl Health Econ Health Policy. 2011 Nov 1;9(6):403-17. doi: 10.2165/11592210-000000000-00000. Review.

PMID:
21910511
44.

The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective.

Pollock RF, Valentine WJ, Pilgaard T, Nishimura H.

J Med Econ. 2011;14(1):36-46. doi: 10.3111/13696998.2010.541045. Epub 2010 Dec 31.

PMID:
21192769
45.

Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes.

Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ.

Curr Diabetes Rev. 2011 Jan;7(1):61-74. Review.

PMID:
21143106
46.

Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents.

Pollock RF, Valentine WJ, Goodall G, Brändle M.

Swiss Med Wkly. 2010 Oct 25;140:w13103. doi: 10.4414/smw.2010.13103. eCollection 2010.

47.

Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.

Valentine WJ, Pollock RF, Plun-Favreau J, White J.

Curr Med Res Opin. 2010 Jun;26(6):1399-412. doi: 10.1185/03007991003689381. Review.

PMID:
20387997
48.

BioSAVE: display of scored annotation within a sequence context.

Pollock RF, Adryan B.

BMC Bioinformatics. 2008 Mar 20;9:157. doi: 10.1186/1471-2105-9-157.

Supplemental Content

Loading ...
Support Center